Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...

Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.

Please provide your email address to receive an email when new articles are posted on . Most patients with nonsquamous NSCLC treated at academically-affiliated community clinics received ...

Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting ...

Exploring barriers to completing referral appointments for cancer genetic services in a rural state. Is federal housing assistance associated with earlier-stage cancer diagnosis? Evidence from the new ...

FORT MYERS, Fla., May 22, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, today announced the commercial launch of c-MET CDx for NSCLC, its ...

FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ: NEO), a provider of cancer testing services with annual revenue of $672 million and healthy liquidity metrics, has introduced a new diagnostic assay, ...